Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Kissei Pharmaceutical Co ( (JP:4547) ) has issued an announcement.
Kissei Pharmaceutical reported a 10.6% year-on-year rise in net sales to ¥72.6 billion for the nine months ended December 31, 2025, but swung to operating and ordinary losses despite higher revenue, while profit attributable to owners of parent increased 24.6% to ¥11.0 billion, supported by factors below the operating line and driving basic earnings per share up to ¥264.77. The company strengthened its financial position with total assets rising to ¥259.6 billion and equity reaching ¥216.4 billion, and it revised its dividend plan to include a substantial increase in total annual payouts to ¥160 per share for the fiscal year ending March 31, 2026, incorporating a commemorative dividend for its 80th anniversary, signaling a shareholder-friendly capital policy even as it forecasts a full-year operating loss.
The most recent analyst rating on (JP:4547) stock is a Hold with a Yen4900.00 price target. To see the full list of analyst forecasts on Kissei Pharmaceutical Co stock, see the JP:4547 Stock Forecast page.
More about Kissei Pharmaceutical Co
Kissei Pharmaceutical Co., Ltd. is a Japan-based drugmaker listed on the Tokyo Stock Exchange, operating under Japanese GAAP. The company develops, manufactures and sells pharmaceutical products, with a focus on prescription drugs, and maintains a strong equity base and high equity ratio, reflecting a conservative financial structure in the domestic healthcare market.
Average Trading Volume: 66,884
Technical Sentiment Signal: Buy
Current Market Cap: Yen185B
See more data about 4547 stock on TipRanks’ Stock Analysis page.